Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation
Journal of Obstetrics and Gynaecology Research · 2023
DOI: 10.1111/jog.15663 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2023. Verfasst von Takashi Nei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
This study analyzed a 63‐year‐old woman with hereditary BRCA1 mutation. She underwent interval debulking surgery after neoadjuvant chemotherapy for high‐grade serous ovarian carcinoma (HGSOC). After 2 years of postoperative chemotherapy, she developed headache and dizziness, and a suspected metastatic cerebellar mass in left ovary was detected. Pathological analysis of the mass revealed HGSOC, which was removed surgically. Eight months and another 6 months after the surgery, local recurrence was noted; hence, she underwent CyberKnife treatment. After 3 months, cervical spinal cord metastasis was found, evidenced by left shoulder pain. Moreover, meningeal dissemination was present around the cauda equina. Chemotherapy treatment, including bevacizumab, was ineffective and increased lesions were observed. After CyberKnife treatment for the cervical spinal cord metastasis, niraparib was initiated for the meningeal dissemination. The cerebellar lesions and meningeal dissemination improved within 8 months of niraparib treatment. Although meningeal dissemination is challenging to treat, niraparib may be useful in BRCA ‐mutated HGSOC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
ORCID-Profile: Satoshi Tamauchi, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kaoru Niimi, Hiroaki Kajiyama
Zitieren
APA
Nei, T., Tamauchi, S., Ikeda, Y., Yoshikawa, N., Niimi, K., & Kajiyama, H. (2023). Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15663
Vancouver
Nei T, Tamauchi S, Ikeda Y, Yoshikawa N, Niimi K, Kajiyama H. Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation. Journal of Obstetrics and Gynaecology Research. 2023. doi:10.1111/jog.15663
BibTeX
@article{Nei2023,
author = {Nei, Takashi and Tamauchi, Satoshi and Ikeda, Yoshiki and Yoshikawa, Nobuhisa and Niimi, Kaoru and Kajiyama, Hiroaki},
title = {Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2023},
doi = {10.1111/jog.15663}
}
EUVIMED